Compare Globus Medical Inc. Class A Common Stock (GMED) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs KB Financial Group, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while KB Financial Group, Inc. trades at $115.32 (market cap $41.70B). The key difference: KB Financial Group, Inc. is far larger — about 4.1× Globus Medical Inc. Class A Common Stock's market cap, and KB Financial Group, Inc. pays a 2.83% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and KB Financial Group, Inc. for 33 Days on average.
| GMED | KB | |
|---|---|---|
Market Cap | $10.25B | $41.70B |
Volume | 1,059,528 | 251,007 |
Sector | Health | Financials |
52-Week High | $96.82 | $132.88 |
52-Week Low | $58.33 | $80.15 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $9.76B | $213.39T |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
KB Financial trades at $121.44, down 0.44% today, with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth continues from $21.23T in 2025 to projected $22.37T in 2026, while net margins improved to 27.47%. Analyst consensus shows 33% buy ratings with 67% hold, indicating cautious optimism despite technical weakness.
KB presents a value opportunity with attractive valuation metrics including P/E of 9.24 and P/B of 0.9, trading below book value. The main risks include South Korean economic exposure and banking sector volatility, while catalysts include continued earnings momentum and institutional accumulation as seen in Nykredit's recent $10.9M position acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
